Cann (ASX:CAN) share price continues to rise despite product recall

The Cann Group Ltd (ASX: CAN) share price is holding its ground today despite announcing a product recall from one of its customers. Here's the details.

| More on:
A graphic showing a rising share price in medical cannabis shares

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cann Group Ltd (ASX: CAN) share price is holding its ground today despite announcing a product recall from one of its customers.

During late afternoon trade, the cannabis company's shares are fetching for 48.5 cents, up 1%. At one point, Cann shares reached an intraday high of 51 cents, before heading lower.

What happened?

Investors appear unfazed by the company's latest announcement, keeping Cann shares in the green today.

Cann advised that one of its customers has commenced a class III recall for its 50ml medicinal cannabis oil products.

According to the Australian Therapeutic Goods Administration, a class III product recall is defined as follows:

Class III – Lowest risk – recall action occurs when the use of, or exposure to, the deficient therapeutic good(s) is not likely to cause adverse health consequences and they are therefore not safety-related.

Cann stated that 250 units of the recalled products were recently released to the Australian market. It noted that 11 units have been given to patients, with the remaining units being held by the customer's distributor.

The products were manufactured and released by an approved third-party GMP licenced manufacturer, using ingredients from another third-party. Cann explained that the recall follows a similar batch of the product in which was notified by the manufacturer.

The sponsor of the product in Australia (the customer's distributor) is currently in discussions with the TGA to coordinate the recall. Cann said that it's working with the affected supply chain, and the customer to identify the cause of the issue.

About the Cann share price

Over the last 12 months, the Cann share price has almost halved in value, dragging down shareholder gains. Year-to-date has fared no better with the company's shares down close to 20%.

On valuation grounds, Cann presides a market capitalisation of around $134 million, with roughly 277.8 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »